77
Participants
Start Date
October 25, 2021
Primary Completion Date
June 11, 2024
Study Completion Date
June 11, 2024
CNTX-6970
CNTX-6970, a novel potent antagonist of CCR2 with lesser effects on CCR5, is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
Placebo
BID
New York University Langone Health, New York
Icahn School of Medicine at Mount Sinai, New York
Montefiore Medical Center, The Bronx
University of Rochester, Rochester
University of Pittsburgh, Pittsburgh
University of Pennsylvania, Philadelphia
Center for Clinical Research, Winston-Salem
University of Florida, Gainesville
M&M Clinical Trials, Miami
Healthcare Research Network, Hazelwood
UTsouthwestern Medical Center, Dallas
University of California San Diego, La Jolla
University of California- Davis, Sacramento
University of Washington, Seattle
Massachusetts General Hospital, Boston
University of Wisconsin- Madison, Madison
Maurizio Fava, MD
OTHER